Bulletin
Investor Alert

Market Pulse Archives

July 2, 2021, 12:27 p.m. EDT

Mizuho: Merck withdrawing Keytruda as a gastric cancer treatment won't impact the stock

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Merck & Co. Inc. /zigman2/quotes/209956077/composite MRK -0.40% were up 0.7% in trading on Friday, the day after the company said it will voluntarily withdraw an accelerated approval for Keytruda as a third-line treatment for some patients with gastric cancer in the next six months. Keytruda is Merck's top-selling drug; it brought in $14.4 billion in sales in 2020. The decision to withdraw the drug for this indication is part of the Food and Drug Administration's efforts to assess whether certain cancer medicines that received a type of approval dependent on confirmatory post-market clinical studies should stay on the market. The withdrawal is not expected to have a material impact on company shares, according to Mizuho Americas analysts. Merck's stock is up 0.7% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.91% is up 14.4%.

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 71.68
-0.29 -0.40%
Volume: 43.42M
Sept. 17, 2021 4:03p
P/E Ratio
32.72
Dividend Yield
3.63%
Market Cap
$181.45 billion
Rev. per Employee
$648,824
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,432.99
-40.76 -0.91%
Volume: 3.79B
Sept. 17, 2021 5:25p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.